SCHEMBL3547435

SCHEMBL3547435

CCCc1cc(OC)cc(C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.46
PTGS2 P35354 1/20 0.46
RXRA P19793 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.44
PKM P14618 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
KDM4E B2RXH2 1/20 0.42
CA12 O43570 1/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10472668 0.87 PTGS2 (0.60) PLA2G2APTGS2ALDH1A1KMT2ACNR1
SCHEMBL27999944 0.86 RXRA (0.47) PLA2G2APTGS2RXRAMRGPRX4PKM
SCHEMBL3553070 0.85 CA1 (0.46) PTGS2SMN1; SMN2NFKB1NFKB2RELA
SCHEMBL1355567 0.83 ALDH1A1 (0.45) PLA2G2ARXRARAB9ASMN1; SMN2TP53
SCHEMBL7769260 0.83 RXRA (0.46) PLA2G2ARXRARAB9ASMN1; SMN2TP53
SCHEMBL57366 0.82 RXRA (0.47) PTGS2RXRAMRGPRX4PKMRAB9A
SCHEMBL16961469 0.82 PTGS2 (0.49) PTGS2ALDH1A1CALM1CNR1CNR2
SCHEMBL14288600 0.82 PLK1 (0.54) PTGS2SMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL12480647 0.81 RXRA (0.46) PLA2G2APTGS2RXRAMRGPRX4PKM
SCHEMBL5270681 0.81 CA1 (0.47) PTGS2RXRAMRGPRX4PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PLA2G2A 4096/4885PTGS2 3204/4885RXRA 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.